获取途径

作者

Yutong Zou, Yifei Wang, Xiaoli Ma, Danni Mu, Jian Zhong, Chaochao Ma, Chenhui Mao, Songlin Yu, Jing Gao, Ling Qiu

作者单位

Department of Pathology and Lab Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan 250117, Shandong, China. ² Department of Laboratory Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China. ³ Department of Neurology, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China. ⁴ Department of Laboratory Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address: yusonglinpku@16 State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address: qiul@pumch.cn. Affiliations ¹ Department of Laboratory Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China com. ⁵ Department of Laboratory Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China

刊名

Ageing research reviews

年份

2024

卷号

Vol.101

页码

102485

ISSN

1872-9649

关键词

Alzheimer's disease Blood Cerebrospinal fluid Diagnostic reviews Glial fibrillary acidic protein.

摘要

Recently included in the 2024 new revised diagnostic criteria of Alzheimer's disease , glial fibrillary acidic protein has garnered significant attention. A systematic review and meta-analysis were performed to comprehensively evaluate the diagnostic, differential diagnostic, and prospective diagnostic performance of GFAP in cerebrospinal fluid and blood for AD continuum. A literature search using common electronic databases, important websites and historical search way was performed from ince...更多

Recently included in the 2024 new revised diagnostic criteria of Alzheimer's disease , glial fibrillary acidic protein has garnered significant attention. A systematic review and meta-analysis were performed to comprehensively evaluate the diagnostic, differential diagnostic, and prospective diagnostic performance of GFAP in cerebrospinal fluid and blood for AD continuum. A literature search using common electronic databases, important websites and historical search way was performed from inception to the beginning of March 2023. The inclusion criteria was studies evaluating the diagnostic accuracy of GFAP in CSF and/or blood for the AD continuum patients, utilizing PET scans, CSF biomarkers and/or clinical criteria. The systematic review and meta-analysis were conducted referring to the Cochrane Handbook. In total, 34 articles were eventually included in the meta-analysis, 29 of which were published within the past three years. Blood GFAP exhibited good diagnostic accuracy across various AD continuum patients, and the summary area under curve for distinguishing PET positive and negative individuals, CSF biomarkers defined positive and negative individuals, clinically diagnosed AD and cognitive unimpaired controls, AD and/or mild cognitive impairment and other neurological diseases, and prospective cases and controls was 0.85[0.81-0.88], 0.77[0.73-0.81], 0.92[0.90-0.94], 0.80[0.77-0.84], and 0.79[0.75-0.82], respectively. Only several studies were recognized to evaluate the diagnostic accuracy of CSF GFAP, which was not as good as that of blood GFAP , but its accuracy remarkably increased to AUC = 0.91 when combined with other factors like sex, age, and ApoE genotype. In summary, GFAP, particularly in blood, shown good diagnostic, differential diagnostic, and prospective diagnostic accuracy for AD continuum patients, with improved accuracy when used alongside other basic indexes.收起

文献类型

期刊